DUBLIN - April 5, 2018 - Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced Laura Mauri, M.D., M.Sc., interventional cardiologist and clinical researcher at the Brigham and Women's Hospital, and professor of medicine at Harvard Medical School, will join Medtronic as Vice President, Global Clinical Research & Analytics. Dr. Mauri will direct the company's dynamic global clinical research strategies which leverage her widely recognized clinical trial leadership and deep domain expertise in medical technology evaluation and clinical research methodology.

Dr. Mauri will lead the development of novel analytical and data science solutions at Medtronic to address the expanding global requirements for clinical evidence for our products. She will also lead initiatives supporting the value-based healthcare strategies that Medtronic is pioneering to meet the growing broad-based stakeholder demand for outcomes accountability. She will officially assume this role on September 1, 2018 and report to Rick Kuntz, M.D., M.Sc., chief medical and scientific officer.

"We are excited to welcome Dr. Mauri to Medtronic. She is an accomplished front-line clinician, and widely recognized academic clinical researcher and medical thought leader," said Omar Ishrak, chief executive officer of Medtronic. "Her scientific and clinical expertise will greatly contribute to our ability to fulfill our mission to alleviate pain and restore health."

Dr. Mauri has served as chief scientific officer of the Harvard Clinical Research Institute. Her research regarding new medical device effectiveness has helped shape clinical evaluation of new medical technologies, providing a greater understanding of the interactions between medical devices, general clinical practice, and concurrent pharmaceutical therapies. She has led clinical trials to evaluate novel medical devices and pharmaceuticals, and is an expert in trial design, strategy and data analysis. Her innovative work has also influenced international medical guidelines and has been published in the New England Journal of Medicine, among other high-impact medical journals, and is presently a senior associate editor for Circulation, contributing to the editorial oversight of the journal's content.

"Dr. Mauri is a highly respected physician and researcher who has served as a principal investigator on multiple major clinical studies and has generated novel original research in clinical trial methodologies. She will allow us to expand our scientific strategies for evidence development and to explore new frontiers in data science," said Dr. Kuntz. "In today's dynamic healthcare landscape, including the trend toward value-based healthcare, innovative leaders such as Dr. Mauri assure we continue to be on the leading edge of medical technology and healthcare solutions."

Dr. Mauri is a member of the American Society of Clinical Investigation, the Association of University Cardiologists, the American Heart Association, and the Society of Cardiac Angiography and Intervention. She is a Fellow of the American College of Cardiology. She received her A.B. from Harvard College and her M.D. from Harvard Medical School, and her M.Sc. (Clinical Epidemiology) from Harvard School of Public Health. She completed residency in internal medicine, fellowship in cardiovascular diseases and interventional cardiology, at the Brigham and Women's Hospital and Harvard Medical School in Boston.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:
Fernando Vivanco
Public Relations
+1-763-505-3780

Ryan Weispfenning
Investor Relations
+1-763-505-4626